VIPR2 antagonist peptide

Abstract

A VIPR2 antagonist peptide includes a cyclic peptide comprising an amino acid sequence represented by formula (17): c[X1-Pro-X3-Tyr4-Leu5-Pro6-c(X7-X8-Leu9-Cys10]-X11)-X12-X13 (17), wherein X1 denotes cysteine, Mpa (3-mercaptopropionic acid), or D-cysteine; X3 denotes N-methylglycine, N-methylalanine, 2-azetidine-2-carboxylic acid, proline, hydroxyproline, 3,4-dehydroprolone, pipecolic acid, serine, or lysine; X8 denotes tyrosine, proline, or arginine; X7 and X11 denotes any combination of lysine and aspartic acid, ornithine and glutamic acid, aspartic acid and lysine, glutamic acid and ornithine, lysine and glutamic acid, or glutamic acid and lysine; X12 and X13, each independently denotes leucine, isoleucine, or norleucine; X1 and Cys10 form a disulfide bond between their side chains, and X7 and X11 form an amide bond between their side chains, thereby forming two cyclic structures in a molecule of the peptide of formula (17); and an N-terminal amino group and a C-terminal carboxyl group may be modified.

Dependencies are inferred from the claim text.